Corey Manley Sells 5,025 Shares of Omnicell (NASDAQ:OMCL) Stock

Omnicell, Inc. (NASDAQ:OMCL) EVP Corey Manley sold 5,025 shares of the firm’s stock in a transaction that occurred on Monday, May 18th. The stock was sold at an average price of $43.22, for a total transaction of $217,180.50. Following the completion of the sale, the executive vice president owned 112,783 shares in the company, valued at $4,874,481.26. This represents a 4.27% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Omnicell Trading Up 2.1%

Shares of OMCL stock opened at $44.72 on Thursday. Omnicell, Inc. has a 12-month low of $26.84 and a 12-month high of $55.00. The company has a current ratio of 1.50, a quick ratio of 1.29 and a debt-to-equity ratio of 0.13. The firm’s 50 day moving average is $37.80 and its 200 day moving average is $40.68. The stock has a market capitalization of $2.03 billion, a P/E ratio of 101.64, a P/E/G ratio of 1.13 and a beta of 0.96.

Omnicell (NASDAQ:OMCL) last issued its earnings results on Tuesday, April 28th. The company reported $0.55 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.33 by $0.22. Omnicell had a net margin of 1.67% and a return on equity of 4.00%. The company had revenue of $309.88 million for the quarter, compared to analysts’ expectations of $304.02 million. During the same quarter last year, the company posted $0.26 earnings per share. The firm’s quarterly revenue was up 14.9% on a year-over-year basis. Omnicell has set its FY 2026 guidance at 1.800-2.000 EPS and its Q2 2026 guidance at 0.400-48.000 EPS. Research analysts expect that Omnicell, Inc. will post 1.31 earnings per share for the current year.

Analysts Set New Price Targets

Several brokerages recently issued reports on OMCL. Zacks Research upgraded shares of Omnicell from a “hold” rating to a “strong-buy” rating in a report on Friday, May 1st. Benchmark restated a “buy” rating on shares of Omnicell in a report on Friday, March 13th. Bank of America upgraded shares of Omnicell from a “neutral” rating to a “buy” rating and set a $70.00 target price on the stock in a report on Wednesday, February 4th. KeyCorp lifted their price target on shares of Omnicell from $60.00 to $70.00 and gave the stock an “overweight” rating in a research note on Tuesday, April 28th. Finally, Weiss Ratings upgraded shares of Omnicell from a “sell (d)” rating to a “hold (c-)” rating in a research note on Thursday, May 7th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $59.86.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. Wellington Management Group LLP increased its stake in Omnicell by 156.4% in the 4th quarter. Wellington Management Group LLP now owns 2,075,362 shares of the company’s stock worth $94,014,000 after buying an additional 1,265,818 shares in the last quarter. Millennium Management LLC bought a new stake in Omnicell during the third quarter valued at about $25,625,000. First Light Asset Management LLC bought a new stake in Omnicell during the first quarter valued at about $16,351,000. Boston Partners bought a new stake in Omnicell during the fourth quarter valued at about $20,805,000. Finally, WCM Investment Management LLC bought a new stake in Omnicell during the first quarter valued at about $9,783,000. Hedge funds and other institutional investors own 97.70% of the company’s stock.

About Omnicell

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.